Bupropion News and Research

RSS

Anti-obesity medications could help treat alcohol use disorders

Losing weight with anti-obesity medications (AOM) also resulted in decreased alcohol consumption for about half of the participants in a new study appearing in the current issue of JAMA Network Open.

4 Dec 2024

Nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication

Researchers evaluate changes in alcohol use after initiating antiobesity medication.

29 Nov 2024

IQWiG evaluates smoking cessation drugs for severe tobacco dependence treatment

By law, smokers with severe tobacco dependence are entitled to receive one-off drug therapy for smoking cessation as part of evidence-based programmes reimbursed by the German statutory health insurance (SHI).

27 Nov 2024

Safe storage crucial to prevent child drug poisoning

New data shows that the number of children suffering a seizure after swallowing medications or illegal substances has doubled between 2009 and 2023 in the US. The findings were presented today (Wednesday) at the European Emergency Medicine Congress.

16 Oct 2024

Best ways to quit smoking: E-cigs, medications, and counseling proven effective in new Cochrane analysis

Recent Cochrane reviews highlight effective smoking cessation interventions, revealing gaps in research and the need for improved tobacco addiction strategies.

9 Sep 2024

New review highlights top strategies for smoking cessation

A major new scientific review of evidence published in the journal Addiction has identified three top strategies for quitting smoking.

5 Sep 2024

European Society of Cardiology highlights underrecognized link between obesity and heart disease

Obesity is a key factor in cardiovascular disease, prompting the ESC to recommend comprehensive strategies for prevention and management to reduce health risks.

3 Sep 2024

ESC consensus statement highlights obesity's impact on cardiovascular disease

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2 September) summarizes current evidence on the epidemiology and etiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes.

30 Aug 2024

Researchers urge inclusion of marginalized groups to bridge bulimia nervosa treatment gaps

Researchers identified significant disparities in bulimia nervosa treatment, urging more inclusive research to address gaps in care for marginalized populations.

16 Aug 2024

Semaglutide linked to increased risk of severe eye condition NAION in new study

Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity.

8 Jul 2024

WHO recommends a comprehensive set of tobacco cessation interventions

The World Health Organization (WHO) recommends a comprehensive set of tobacco cessation interventions, including behavioral support delivered by health-care providers, digital cessation interventions and pharmacological treatments in a first guideline on tobacco cessation.

2 Jul 2024

Clinical trial demonstrates efficacy of two-drug therapy for methamphetamine addiction

A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment, UCLA-led research suggests.

10 Jun 2024

New AI tool analyzes medical history to match patients with best antidepressant

Researchers in George Mason University's College of Public Health have leveraged the power of artificial intelligence (AI) analytical models to match a patient's medical history to the most effective antidepressant, allowing patients to find symptom relief sooner.

30 May 2024

Enhanced weight loss outcomes with GLP-1 analogues and bupropion/naltrexone combination

A study explores the additive effects of combining GLP-1 analog with bupropion/naltrexone on weight loss, finding potential benefits even for those initially unresponsive to monotherapy.

13 May 2024

Disruption of smoking cessation medicine linked to avoidable deaths

The disruption to the supply of a prescription medicine that helps people stop smoking may have led to thousands fewer people quitting each year in England, which will lead to avoidable deaths in future, suggests a new study led by UCL (University College London) researchers.

30 Apr 2024

Study: Most stroke survivors can safely take two types of common antidepressants

Most stroke survivors were able to safely take two types of common antidepressants, according to a preliminary study to be presented at the American Stroke Association's International Stroke Conference 2024.

1 Feb 2024

Tirzepatide shows success in maintaining weight loss in obese adults

Study finds that the anti-obesity medication tirzepatide effectively maintains weight loss in obese adults, offering a promising approach to managing obesity and related health complications.

12 Dec 2023

Intracellular journey: The penetration of antidepressants into cells, organelles, and membranes

Researchers in neuropsychopharmacology challenge conventional wisdom about antidepressants' actions, revealing significant intracellular activity that influences their effectiveness. Utilizing advanced technologies, the study prompts a reevaluation of drug targeting and mechanisms, opening new avenues for treating depression.

12 Oct 2023

GLP-1 weight loss drugs linked to heightened GI risks, says new study

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

5 Oct 2023

GLP-1 agonists linked to higher risk for gastrointestinal complications

They're being hailed as an effective way to lose weight, but diabetes drugs like Ozempic may come with a heightened risk of severe gastrointestinal problems.